

# **L** Core Project R030D030604

#### O Details

Projects	Name	Award	Publications	Repositories	Analytics
1R03OD030604-01	Using Common Fund data to inform rare disease preclinical models and prioritize drug repurposing	\$297,000.00	9 publications	0 repositories	0 properties

## Publications

Published works associated with this project.

ID	Title	Authors	R C R	SJ R	Cita tion s	Cit./ yea r	Journal	Publ ishe d	Updat ed
35337371 🗹	Considerations and challenges for sexaware drug repurposing.	Jennifer L Fisher	1. 41	0	9	4.5	Biol Sex Differ	2022	Dec 1, 2024

		4 more Brittany N Lasseign e							(2 weeks ago)
37533331 🛂	Evaluating cancer cell line and patient- derived xenograft recapitulation of tumor and non-disease	Avery S Williams2 more Brittany N Lasseign e	0. 96	0	3	3	Cancer Rep (Hoboken)	2023	Dec 1, 2024 (2 weeks ago)
36602970 <b>2</b> DOI <b>2</b>	Ten simple rules for using public biological data for your research.	Vishal H Oza 9 more Brittany N Lasseign e	0. 56	0	2	2	PLoS Comput Biol	2023	Dec 1, 2024 (2 weeks ago)
37824797 <b>乙</b>	Computational Advancements in Cancer Combination Therapy Prediction.	Victoria L Flanary 3 more Brittany	0. 43	0	2	2	JCO Precis Oncol	2023	Dec 1, 2024 (2 weeks ago)

		N Lasseign e							
37217845 <b>亿</b> DOI <b>亿</b>	Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and	Elizabeth J Wilk 9 more Brittany N Lasseign e	0. 36	0	1	1	Mol Med	2023	Dec 1, 2024 (2 weeks ago)
38167211 ♂ DOI ♂	Sex-biased gene expression and gene- regulatory networks of sex-biased adverse event drug targets	Jennifer L Fisher 2 more Brittany N Lasseign e	0	0	0	0	BMC Pharmacol Toxicol	2024	Dec 1, 2024 (2 weeks ago)
37090499 <b>乙</b> DOI <b>乙</b>	Evaluating cancer cell line and patient- derived xenograft recapitulation of tumor and non-disease	Avery S Williams2 more Brittany N Lasseign e	0	0	0	0	bioRxiv	2023	Dec 1, 2024 (2 weeks ago)


37362157 🗗 DOI 🗗	Sex-biased gene expression and gene- regulatory networks of sex-biased adverse event drug targets	Jennifer L Fisher 2 more Brittany N Lasseign e	0	0	0	0	bioRxiv	2023	Dec 1, 2024 (2 weeks ago)
<u>38531616</u> <b>♂</b> DOI <b>♂</b>	Signature reversion of three disease- associated gene signatures prioritizes cancer drug repurposi	Jennifer L Fisher 7 more Brittany N Lasseign e	0	0	0	0	FEBS Open Bio	2024	Dec 1, 2024 (2 weeks ago)

#### Notes

RCR Relative Citation Ratio

SJR Scimago Journal Rank

Publications (cumulative)



Name	Tags	Last Commit	Avg Issue	Avg PR	Languages	License	Readme	Contributing	Dependencies
					No data				

#### Notes

Repository For storing, tracking changes to, and collaborating on a piece of software.

PR "Pull request", a draft change (new feature, bug fix, etc.) to a repo.

Closed/Open Resolved/unresolved.

Avg Issue/PR Average time issues/pull requests stay open for before being closed.

Only the main /default branch is considered for metrics like # of commits.

# of dependencies is totaled from all manifests in repo, direct and transitive, e.g. package.json + package-lock.json.

## Analytics

Traffic metrics of websites associated with this project.

#### Notes

Active Users <u>Distinct users who visited the website</u> 2.

New Users <u>Users who visited the website for the first time</u> **.** 

Engaged Sessions <u>Visits that had significant interaction</u> **?**.

"Top" metrics are measured by number of engaged sessions.

Generated on Dec 14, 2024

Developed with support from NIH Award U54 OD036472